Health Trials

Fosrolapitant and Palonosetron for the Prevention of Antibody-drug Conjugate-induced Nausea and Vomiting

ConditionNausea and Vomiting Induced by Antibody-drug Conjugates (ADCs)
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorPeking University Cancer Hospital & Institute

About this trial

This study is aimed to evaluate the efficacy and safety of Fosrolapitant and Palonosetron for Antibody-drug conjugate-induced nausea and vomiting

Eligibility criteria

Qualifiers

None

Disqualifiers

18 years of age or older, of either gender

Has a diagnosed malignant tumor

has never been treated with ADCs and is to receive the first course of ADCs

Predicted life expectancy of ≥ 3 months

Trial design

Treatments tested in this trial

  • Fosrolapitant and Palonosetron for injection

Treatment groups

124 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Peking University Cancer Hospital & Institute

Lead sponsor

Source ClinicalTrials.gov